Picture of Aktis Oncology logo

AKTS — Aktis Oncology News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMid CapSucker Stock

Brief: Akoustis Reports Fifth Consecutive Quarter Of Record Revenue As Second Quarter Fiscal 2023 Sales Grew Over 59% Year-Over-Year

Feb 7 (Reuters) - Akoustis Technologies Inc  AKTS.O :
    * AKOUSTIS REPORTS FIFTH CONSECUTIVE QUARTER OF RECORD
REVENUE AS
SECOND QUARTER FISCAL 2023 SALES GREW OVER 59% YEAR-OVER-YEAR
    * QUARTERLY REVENUE ROSE 59 PERCENT TO $5.9 MILLION
    * QTRLY NET LOSS PER COMMON SHARE - BASIC AND DILUTED $0.19
    * Q2 EARNINGS PER SHARE VIEW $-0.25, REVENUE VIEW $5.9
MILLION --
REFINITIV IBES DATA

Source text for Eikon:  ID:nGNX9gyn7G 
Further company coverage:  AKTS.O 
 ((Reuters.Briefs@thomsonreuters.com;))

Recent news on Aktis Oncology

See all news